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Abstract Ceramide and sphingosine-1-phosphate (S1P), two
important bioactive sphingolipids, have been suggested as
being key players in the pathology of Alzheimer’s disease in
inflammation and cancer. However, their role in the molecular
mechanisms of neuronal death has not been fully elucidated.
Our study indicated that ceramide significantly enhanced the
level of free radicals and decreased the viability of the human
neuroblastoma cell line (SH-SY5Y) through inhibition of the
prosurvival PI3-K/Akt pathway. Ceramide also decreased
anti-apoptotic (Bcl-2) and increased pro-apoptotic (Bax,
Hrk) mRNA/protein levels. Concomitantly, our study indicat-
ed that ceramide induced poly(ADP-ribose) polymerase-1
(PARP-1) activation and accumulation of poly(ADP-ribose)
PAR, a signalling molecule involved in mitochondria-nucleus
cross-talk and mitochondria integrity. Ceramide treatment
significantly decreased the level of apoptosis-inducing factor
(AIF) in the mitochondria. The PARP-1 inhibitor (PJ-34)
prevented AIF release from the mitochondria. In addition,
our data showed that exogenously added S1P increased the
viability of SH-SY5Y through the S1P (1,3) receptor-
dependent mechanism. It was also revealed that the S1P and
PARP-1 inhibitor (PJ-34) decreased oxidative stress, gene
expression of the pro-apoptotic Hrk protein and up-regulated
the anti-apoptotic Bcl-2 protein. Our data demonstrate
that neuronal cell death evoked by ceramide is regulated
by PARP/PAR/AIF and by S1P receptor signalling. In
summary, our results suggest that PARP-1 inhibitor(s)
and modulators of sphingosine-1-phosphate receptor(s)
should be considered in potential therapeutic strategies
directed at neurodegenerative diseases.
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Introduction
Ceramides are a class of sphingolipids that are abundant in cell
membranes and play an important role in regulation of the
fluidity and structure of the lipid bilayer. During the last
decade, ceramides have been recognised as very important
second messengers for multiple extracellular stimuli mediat-
ing many cellular processes, mainly those associated with the
regulation of cell proliferation, differentiation, growth arrest
and apoptosis [1–3]. Ceramides are composed of a sphingoid
base linked to a fatty acid of varying chain length (14–26
carbons) via an amide bond. Cell-permeable short chain cer-
amide, C2-ceramide and C6-ceramide have been used in
many studies to mimic ceramide-mediated cell death path-
ways. It was shown that C2-ceramides were present naturally
in the brain at low levels [4]. Treatment of neuronal cells with
ceramides at low concentration promotes cell differentiation,
survival and neurite outgrowth, while at higher concentration
it induces apoptosis. Downstream targets of ceramides are
diverse and not completely characterised. It has been de-
scribed that ceramide regulates mitogen-activated protein ki-
nase (MAPK), protein kinase ζ (PKCζ), stress-activated pro-
tein kinases (SAPK/c-Jun N-terminal kinases (JNK)),
ceramide-activated protein kinases (CAPK), ceramide-
activated protein phosphatase (CAPP) and phospholipases
(cPLA, PLD, PLA2) [5–9]. Ceramides are generated by three
metabolic pathways: de novo synthesis, sphingomyelin hydro-
lysis and the salvage pathway [1]. These pathways are acti-
vated in response to oxidative stress, tumour necrosis
factor-α, chemotherapeutic agents and radiation. Ceramide
may be broken down by ceramidases, thus leading to the
formation of sphingosine, which can be phosphorylated by
sphingosine kinases (Sphk1and Sphk2) to sphingosine-1-
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phosphate (S1P). It is known that S1P acts in an autocrine/
paracrine manner via a family of five S1P-specific cell-surface
G-protein-coupled receptors (GPCRs, termed S1P1-5) [10,
11]. S1P signalling through these receptors activates the
PI3K/Akt pathway and Ras/extracellular signal-regulated ki-
nases (ERK) to promote proliferation and to prevent apoptosis
[12, 13]. PI3K/Akt regulates many cellular processes includ-
ing metabolism, proliferation, cell survival, growth and an-
giogenesis [14]. The balance between the levels of ceramide
and S1P, called “ceramide/S1P rheostat”, contributes to the
fate of the cells [15]. Ceramides, through the formation of
channels, have been reported to induct mitochondrial outer
membrane permeabilisation, which is a key event in apoptotic
signalling [16, 17]. Ceramides affect the activities of the
mitochondrial electron transport chain and lead to cellular
energy crisis [18, 19]. This mitochondrial failure evoked by
ceramide leads to enhancement of oxidative stress, DNA
damage and activation of nuclear enzyme poly(ADP-ribose)
polymerase-1 (PARP-1). It was reported previously that the
formation of long-chain poly(ADP-ribose) (PAR) and the
release of the apoptosis-inducing factor (AIF) from
mitochondria to nucleus may accelerate cell death [20–25].
A number of studies have indicated the role of abnormal
sphingolipid metabolism in brain ischemia, inflammation,
Alzheimer’s disease (AD) and other neurodegenerative disor-
ders [26–32]. It was observed in in vivo studies that both a
decrease in the S1P level and ceramide accumulation were
proportional to the degree of cognitive impairment, loss of
intellectual ability and loss of neurons [27, 33, 34]. Ceramides
have been indicated as key player in neuronal cell death;
however, their role is not yet well understood. It has been
demonstrated that neuronal death induced by ceramidemay be
linked to the caspase-9/caspase-3 regulated intrinsic apoptotic
pathway. The data indicated that C2-ceramide in rat primary
cortical neurons induces up-regulation of active caspase-9 and
caspase-3 protein levels [35, 36]. On the other hand, Kim et al.
[37], in human neuroblastoma cell line SY-SY5Y, observed
that the inhibition of caspases was not sufficient to attenuated
ceramide-induced cell death. Ceramide has been also involved
in the control of autophagy [38]. It has been observed that
ceramides activate protein phosphatase PP2A, which in turn
blocks Akt (activation) the well-known autophagy suppressor
[39]. However, the molecular mechanisms of death signalling
pathway evoked by ceramide are not fully elucidated. Addi-
tionally, the role of exogenous S1P in neuroprotection is still
under investigation.
In this study, we investigated the molecular mechanism of
neuronal cell death evoked by ceramide focusing on the
PI3K/Akt/GSK-3β pathway and on PARP-1/AIF signalling
in the human neuroblastoma cell line (SH-SY5Y). The re-
sponse of pro-apoptotic and anti-apoptotic gene expression




The studies were carried out using the human neuroblastoma
cell line (SH-SY5Y) (a kind gift from Prof. Anne Eckert,
Neurobiology Laboratory for Brain Aging andMental Health,
Psychiatric University Clinics, University of Basel). The SH-
SY5Y cells were used for experiments between 5 and 15
passage numbers, cultured in MEM/F-12 Ham Nutrient Mix-
tures (1:1) supplemented with 15 % heat-inactivated fetal
bovine serum (FBS), 1 % penicillin/streptomycin and 2 mM
glutamine. Cells were maintained at 37 °C in a humidified
incubator containing 5 % CO2. For the experiment, confluent
cells were sub-cultured into dishes or collagen coated 96-well
plates. Prior to treatment, the cells were cultivated in low
serum (2% FBS) medium and then were treated with different
inhibitors and compounds.
Cell Treatment Protocols
SH-SY5Y cells were treated with cell-permeable, biologically
active ceramide, C2-ceramide, at a 10 to 50 μM concentration
for various times up to 24 h. In most of the experiments, the
cells were treated with the following compounds: PJ-34
(20 μM), PARP-1 inhibitor; α-pifithrin (20 μM), p53 inhibi-
tor; cyclosporine A (2 μM), inhibitor of the permeability
transition pore; UO126 (1 μM), ERK1/2 kinase inhibitor;
SP600125 (5 μM), JNK kinase inhibitor; sphingosine-1-
phosphate (1 μM), LY294002 (50 μM), PI3-K inhibitor and
Z-DEVD-FMK (100 μM), caspase-3 inhibitor added 1 h be-
fore incubation with C2-ceramide (25 μM). Our data showed
that most of these compounds had no effect on cell viability in
the control condition, with the exception of PARP-1 inhibitor,
JNK kinase inhibitor and PI3-K inhibitor, which significantly
decreased SH-SY5Y cell survival (by about 20 %, PJ-34,
SP600125; 35 %, LY294002). The above-mentioned com-
pounds were purchased from the following: C2-ceramide
and sphingosine-1-phosphate from Enzo Life Sciences,
LY294002 from Cell Signalling Technology, PJ-34, α-
pifithrin, SP600125, U0126 and cyclosporine A from
Sigma-Aldrich, Z-DEVD-FMK from Tocris Bioscence.
Cell Viability Analysis
Cell viability and mitochondrial function were evaluated
using 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT). After 24 h incubation with C2-ceramide
and selected compounds, MTT was added to all of the wells.
The cells were incubated at 37 °C for 2 h, followed by cell
lysis and spectrophotometric measurement at 595 nm.
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Isolation of Cytosolic, Mitochondrial and Nuclear Fractions
Cells were washed and scraped into ice-cold phosphate
buffered saline (PBS) and were pelleted at 1,000×g for
3 min at 4 °C. The pellet was resuspended in hypotonic
buffer (10 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiotreitol, 1.5 mM MgCl2, 10 mM KCl
and protease inhibitors); cell membranes were disrupted
by homogenisation and were pelleted at 500×g for
10 min at 4 °C. The pellet (P1, the crude nuclear
fraction) was resuspended in 25 mM Tris–HCl pH 7.4
with protease inhibitors and was used for Western blot
analysis. A supernatant (S1) was used for isolation of
the mitochondria and the cytosolic fraction by centrifu-
gation at 15,000×g for 10 min at 4 °C. The pellet (P2)
(crude mitochondria) was resuspended in 25 mM Tris–
HCl pH 7.4 with protease inhibitors and was used for
Western blot analysis.
Measurement of PARP-1 Activity
PARP-1 activity was determined using 14C-labelled βNAD+
as a substrate. The incubation mixture, in a final volume of
100 μl, contained 200 μM (adenine-14C)βNAD+ (4×
105 dpm, Amersham Biosciences), 100 mM Tris–HCl buffer
(pH 8.0), 10 mM MgCl2, 5 mM DTT, 50 μM p-APMSF and
50–100 μg of protein. The mixture was incubated for 1 min at
37 °C and the reaction was stopped with 0.8 ml of ice-cold
25 % trichloroacetic acid (TCA). Precipitates were collected
on Whatman GF/B filters, washed three times with 5 % TCA
and left overnight for drying. The radioactivity was measured
using an LKB Wallach 1409 scintillation counter.
Determination of Free Radicals
The fluorescent 2′,7′-dichlorofluorescein (DCF) fluores-
cence assay detects the level of hydrogen peroxide and
other reactive oxygen species (ROS) in cells. Free rad-
icals were determined based on ROS-mediated conver-
sion of 2 ′,7 ′-dichlorodihydrofluorescein diacetate
(H2DCFDA) into DCF [40, 41]. SH-SY5Y cells were
treated with C2-ceramide and selected inhibitors for
24 h and then loaded with 10 μM H2DCFDA in di-
methyl sulfoxide (DMSO) by being incubated for
50 min at 37 °C in Hank’s buffer without Phenol Red
(Sigma–Aldrich, St. Louis MO, USA). DMSO was used
at a final concentration of 0.05 %; at this concentration
it had no effect on the free radical levels. Fluorescence
of DCF was measured using a Perkin Elmer LS 50B
spectrofluorometer with excitation and emission wave-
lengths at 488 and 535 nm, respectively.
Lactate Dehydrogenase Assay Kit
For the analysis of necrotic cell death, a lactate dehydrogenase
(LDH) assay was performed using a commercial LDH cyto-
toxicity Assay Kit II (BioVision) according to manufacturer’s
instructions. After 24 h incubation with C2-ceramide, PJ-34
and S1P cells were centrifuged at 600 g for 10 min. Next, the
clear medium solution was transferred into 96-well plate. To
each well, 100 μl LDH reaction mix were added. After 30 min
incubation at room temperature, the absorbance at 450 nmwas
measured.
Immunochemical Determination of the Protein Level
After protein measurement according to Lowry, the homoge-
nate of SH-SY5Y or the mitochondrial fraction was mixed
with 5× Laemmli sample buffer and denatured for 5 min at
95 °C. Forty to 60 μg of the protein was loaded per lane on
10 % acrylamide gels and examined by sodium dodecyl
sulfate (SDS)–polyacrylamide gel electrophoresis. The pro-
teins were transferred onto polyvinylidene difluoride mem-
branes at 100 V. The membranes were incubated in 5 % dry
milk in TBS with Tween 20 (TBS-T) for 1 h and exposed
overnight to the following antibodies: anti-AIF (from Santa
Cruz Biotechnology, CA, USA), anti-Bcl-2 (from Sigma-
Aldrich, St. Louis, MO, USA), anti-pBad, anti-Bad (from
Santa Cruz Biotechnology), anti-GAPDH (from Sigma–
Aldrich), and anti-Actin (from MP Biomedicals. CA,
USA). After treatment for 1 h with corresponding horse-
radish peroxidase-coupled secondary antibodies (anti-rab-
bit from Sigma–Aldrich or anti-mouse from Amersham
Biosciences), the protein bands were detected by ECL
reagent (ThermoScientific). After detection, the mem-
branes were treated with stripping buffer (50 mM glycine,
pH 2.5, 1 % SDS) for further blots.
Analysis of PAR Immunoreactivity
For the immunochemical detection of PAR formed in vitro,
the cells where homogenized in a cold buffer containing
10 mM Tris–HCl pH 8.0, 50 mM NaCl, 1 mM EDTA,
1 mM DTT and protease inhibitors. The protein homogenate
was pre-incubated for 5 min at 37 °C and then incubated for
1 min in the presence of 100 mM Tris–HCl pH 8.0, 10 mM
MgCl2, 5 mMDTTand 0.2 mM βNAD
+ (a blank sample was
incubated withoutβNAD+). The reaction was terminated with
denaturing sample buffer (5 min at 95 °C) and the
material was subjected to electrophoresis and then trans-
fer as described above. The membrane was blocked in
5 % dry milk and probed with 1:400 anti-PAR antibody
(Alexis Corp., clone#10H) and then with 1:2,000 sec-
ondary horseradish peroxidase-linked anti-rabbit IgG.
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The bands were visualised using the ECL kit and the
level of PAR was measured densitometrically.
Analysis of the mRNA Level
RNA was isolated using TRI-reagent from Sigma-Aldrich.
The isolated RNA was dissolved in RNAse-free water (Ap-
plied Biosystems, Foster City, CA, USA). The amount and
purity of RNAwas determined using spectrophotometric mea-
surement at 260 and 280 nm. The OD260/OD280 ratio 256 of
the RNA samples ranged from 1.6 to 1.9. Isolated RNA (5μg)
was used in reverse transcription polymerase chain reaction.
Reverse transcription was performed by using a High-
Capacity cDNA Reverse Transcription Kit according to the
manufacturer’s protocol (Applied Biosystems). Quantitative
PCR was performed on an ABI PRISM 7500 apparatus by
using pre-developed TaqManGene ExpressionAssays (Applied
Biosystems): actbHs99999903_m1; baxHs00180269_m1; bcl-
2Hs00608023_m1; hrkHs02621354_s1 according to the man-
ufacturer’s instructions. Actb was selected and used in all of the
studies as a reference gene. The relative level of mRNA was
calculated by theΔΔCt method.
Hoechst Immunostaining
For morphological studies, SH-SY5Y cells were subjected for
24 h to oxidative stress evoked by C2-ceramide together with
cytoprotective compounds. Coverslips containing SH-SY5Y
cells were collected and washed in PBS. Nuclei were
visualised with Hoechst 33342 291 (0.2 μg/ml, Riedel-de-
HaënGermany) fluorescent staining. The cells were examined
under a fluorescence microscope (Olympus BX51, Japan) and
photographed with a digital camera (Olympus DP70, Japan).
Statistical Analysis
Statistical analyses between two groups were conducted using
Student’s t test. Analyses among multigroup data were con-
ducted using one-way analysis of variance (ANOVA),
followed by the Newman–Keuls post hoc test. The data
are given as the means±SEM. p values<0.05 were con-
sidered statistically significant.
Results
SH-SY5Y cells were exposed for 24 h to cell-permeable C2-
ceramide. After treatment, cell viability was evaluated by
using MTT assay. The addition of C2-ceramide increased the
level of free radicals and caused neuronal cell death in a
concentration-dependent manner. For further experiments,
C2-ceramide at a concentration of 25 μM used enhancing
oxidative stress by 260 % of the control level and significantly
decreasing cell viability by about 60% (Fig. 1a, b). Our results
indicated that the caspase-3 inhibitor (Z-DEVD-FMK) did not
attenuate the ceramide-induced SH-SY5Y cell death (data not
shown). Signalling through the PI3-K/Akt pathway is critical
for cell survival. We observed that C2-ceramide inactivated
the PI3-K/Akt pathway, thus leading to lower phosphorylation
of glycogen synthase kinase-beta (GSK3β) on serine 9, its
activation and cell death. Exposure to the PI3-K inhibitor
(LY294002) alone or together with C2-ceramide caused SH-
SY5Y cell death. However, LY294002 did not enhance cell
death induced by C2-ceramide (Fig. 2a, b). Oxidative stress
can lead to mitochondrial dysfunction and activation of the
p53-dependent signalling pathway. Therefore, we investigated
the specific inhibitor of p53 (α-pifithrin) and the mitochon-
drial mega-channel (cyclosporine A). Cyclosporine A and α-
pifithrin enhanced neuronal cell survival after C2-ceramide
treatment (Fig. 3). These compounds also significantly re-
duced the level of free radicals (data not shown). Numerous
other cytoprotective compounds were also examined in our
experimental conditions. The data show that the ERK1/2
inhibitor (U0126) and JNK inhibitor (SP600125) significantly
protected the cells against death evoked by C2-ceramide
(Fig. 3). Oxidative stress induced by ceramide can lead to
DNA damage and to activation of the nuclear enzyme PARP-
1. It was observed that C2-ceramide increased PARP-1 activ-
ity up to 170 % of the control level (Fig. 4a). In the next step,
PAR immunoreactivity was evaluated. Our data demonstrated
that C2-ceramide significantly increased the PAR level
(Fig. 4b). Consequently, our data demonstrated that the level
of AIF in the mitochondria was decreased (Fig. 4c). This
effect was more pronounced in cells treated with 50 μM
ceramide (data not shown). A specific PARP-1 inhibitor, PJ-
34, maintained the AIF level in the mitochondria and en-
hanced cell viability (Fig. 4c, d). We also examined the effect
of PJ-34 on ROS production after 24 h of C2-ceramide treat-
ment. Our results also demonstrated that PARP-1 inhibition
significantly reduced the level of free radicals (Fig. 4e).
Looking for a novel, promising neuroprotectant, we used in
the following study S1P, a product of Sphk1 enzymatic activ-
ity, which was expected to activate the pro-survival signalling
pathway. Exogenously added S1P at 1 μM concentration
increased SH-SY5Y cell viability and decreased the ROS
level after C2-ceramide treatment (Fig. 5a, b). The question
arises as to what are the possible mechanisms by which S1P
enhances neuronal cell viability affected by C2-ceramide.
Using a specific receptor antagonist (S1PR1-W123 and
S1PR3-VPC23019), it was observed that the neuroprotective
effect of S1P was in part receptor-dependent (Fig. 5c). More-
over, in the investigated model, we examined the gene
expression/protein level of anti- and pro-apoptotic Bcl-2 pro-
teins. Our data showed that the anti-apoptotic Bcl-2 mRNA
level decreased, but that the pro-apoptotic Bax and Hrk
mRNA level increased after C2-ceramide treatment. PARP-1
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inhibition and exogenously added S1P enhanced the Bcl-2
mRNA/protein level and decreased the Hrk mRNA level
affected by ceramide. However, PJ-34 and S1P had no effect
on the Bax mRNA level (Fig. 6a–c). We also observed that
C2-ceramide decreased the level of the Bcl-2 protein and
induced dephosphorylation of the pro-apoptotic Bad protein
on Ser136, which was reversed by PARP-1 inhibition
(Fig. 7a, b). For evaluation of apoptotic cell death, microscop-
ic examination of cell nuclei stained with DNA-binding fluo-
rochrome Hoechst 33342 was used. The data showed that SH-
SY5Y cells exposed to C2-ceramide presented apoptotic mor-
phology, i.e. condensation of chromatin and nuclear fragmen-
tation. The protective effect of PJ-34 and S1P was observed
(Fig. 8). It is worth to underline that C2-ceramide
significantly increased LDH release. However, we have
C2-ceramide - - + +







Fig. 2 The effect of PI3-K kinase inhibitor (LY294002 {50μM}) on SH-
SY5Y cell viability under oxidative stress evoked by C2-ceramide
(25 μM, 24 h) (a). Data represent the mean value±SEM for three separate
experiments with four to six replications. ***p<0.001 versus control SH-
SY5Y cells by using one-way ANOVA followed by the Newman-Keuls
post hoc test. The effect of C2-ceramide (25 μM, 24 h) on the level of
GSK3β (pSer 9) immunoreactivity (b). Data represent the mean value±
SEM for three separate experiments normalised against GAPDH. Repre-
sentative Western blots from one typical experiment are shown below the
graphs. *p<0.0452 versus control SH-SY5Y cells by Student’s t test
Fig. 3 Evaluation of selected molecular events in neuronal cell
(SH-SY5Y) death evoked by C2-ceramide (25μM, 24 h). The following
specific inhibitors were used: α-pifithrin (20 μM), p53 inhibitor; cyclo-
sporine A (2 μM), inhibitor of the mitochondrial permeability transition
pore; UO126 (1 μM), inhibitor of ERK1/2 kinases; and SP600125
(5 μM), JNK kinase inhibitor. Data represent the mean value±SEM for
three separate experiments with four to six replications. ***p<0.001
versus control SH-SY5Y cells, ###p<0.001, ##p<0.01, #p<0.05 versus
C2-ceramide treated SH-SY5Y cells by using one-way ANOVA followed
by the Newman-Keuls post hoc test
Fig. 1 The effect of C2-ceramide
on SH-SY5Y cell viability (a) and
ROS generation (b) after 24 h
incubation. Data represent the
mean value±SEM for three
separate experiments with four to
six replications (a) and for three
separate experiments with three
replications (b). ***p<0.001,
**p<0.01 versus control SH-
SY5Y cells by using one-way
ANOVA followed by the
Newman-Keuls post hoc test
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not found any protective effect of PJ-34 and S1P (data
not shown).
Discussion
In our current study, the mechanism of ceramide-evoked
neuronal death was analysed. Moreover, the effect of exoge-
nous S1P in molecular alterations induced by ceramide in
neuronal cells SH-SY5Y was evaluated. We demonstrated
that C2-ceramide, through inhibition of PI3K/Akt, influenced
the phosphorylation state of GSK3β and Bad. Neuronal cell
death evoked by ceramide is probably connected with
PI3K/Akt inhibition, which was demonstrated by us using the
PI3K inhibitor. These observations are consistent with a
previous study on SH-SY5Y cells [37]. It was also reported
that the Akt pathway is down-regulated by C2-ceramide in the
NGF-treated PC12 cells as a result of enhanced dephosphory-
lation of Akt1 by protein phosphatase (CAPP-PP2A) [42]. It is
known that Akt phosphorylates and inactivates the pro-
apoptotic Bad protein. This process can contribute to
stabilisation of the mitochondrial membrane. It has been
previously reported that PARP-1 inhibition induced Akt
phosphorylation and activation [43]. Our study showed
that PARP-1 inhibition reversed the effect of C2-
ceramide on Bad phosphorylation probably due to Akt
activation.
Ceramide can exert its effect by modulation of lipid ki-
nases, e.g. JNK [44, 45]. A correlation between increased
ceramide level and JNK activation via phosphorylation has
been reported in differentiated PC-12 cells [46]. JNK activa-
tion and its nuclear translocation in neurons have been report-
ed in vivo in several pathological conditions [44]. The poten-
tial target of pro-apoptotic signalling by JNK is the
a b
Fig. 4 The role of PARP-1 in ceramide toxicity. PARP-1 activity and its
role in oxidative stress and neuronal cell death evoked by C2-ceramide
(25 μM, 24 h) (a). Data represent the mean value±SEM for three separate
experiments with three replications. *p<0.0367 versus control SH-SY5Y
cells by Student’s t test. The effect of C2-ceramide (25 μM, 12 h) on PAR
immunoreactivity in SH-SY5Y cells (b). Data represent the mean value±
SEM for three separate experiments normalised against GAPDH. Repre-
sentative Western blots from one typical experiment are shown below the
graphs. *p<0.0419 versus control SH-SY5Y cells by Student’s t test. The
effect of PARP-1 inhibitor (PJ-34 {20 μM}) on AIF immunoreactivity in
the mitochondrial fraction of SH-SY5Y cells after C2-ceramide treatment
(25 μM, 12 h) (c). Representative Western blots from one typical
experiment are shown below the graphs. Data represent the mean value
±SEM for three independent experiments normalised against β-actin.
*p<0.05 versus control SH-SY5Y cells, ##p<0.01 versus C2-ceramide
treated SH-SY5Y cells by using one-way ANOVA followed by the
Newman-Keuls post hoc test. The effect of PARP-1 inhibitor (PJ-34
{20 μM}) on SH-SY5Y cell viability (d) and ROS generation (e) after
incubation with C2-ceramide (25 μM, 24 h). Data represent the mean
value±SEM for three separate experiments with four to six replications
(d) and for three separate experiments with three replications (e).
***p<0.001 versus control SH-SY5Y cells, ###p<0.001, ##p<0.01 versus
C2-ceramide treated SH-SY5Y cells by using one-way ANOVA followed
by the Newman-Keuls post hoc test
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transcription factor c-Jun. An increase of c-Jun phosphoryla-
tion was found in neuronal nuclei after ceramide treatment [8].
Our results demonstrated that the inhibition of JNK had a
small but statistically significant effect on cell viability in this
stress condition. It has been reported that the JNK signalling
pathway can mediate apoptosis by regulating the expression
of pro-apoptotic Bcl-2 family proteins [47, 48]. Moreover,
Chen et al. [49] demonstrated that amyloid beta peptides
(Aβ), by activation of neutral sphingomyelinase and ceramide
generation, may up-regulate death protein 5 (DP5/Hrk-
harakiri) via JNK action. They observed that the both Aβ
and C2-ceramide rapidly induced Hrk gene expression, in-
creased JNK phosphorylation and AP-1 DNA binding. It is
known that AP-1 DNA-binding consensus sequences are
present in the promoter region of DP5/Hrk. Our finding that
C2-ceramide up-regulated Hrk gene expression is in agree-
ment with this study. Hrk was originally identified as a pro-
apoptotic gene located at 12q13.1 [50, 51]. The role of Hrk in
apoptosis has been described mainly in hematopoietic tissues
and cultured neurons [51, 52]. It has been observed that Hrk
interacts with the anti-apoptotic proteins Bcl-2 and Bcl-XL,
but not with pro-apoptotic Bax or Bak [53] and that apoptosis
by Hrk required the expression of Bax [52]. We provided
evidence, for the first time, that PARP-1 inhibition reduced
the mRNA level of Hrk after C2-ceramide treatment. Recent
data have demonstrated that PARP inhibitors induced the
suppression of JNK in vitro and in vivo [54, 55]. Therefore,
it can be inferred that the effect of the PARP-1 inhibitor (PJ-
34) on Hrk gene expression is associated with the attenuation
of JNK activation. We demonstrated that C2-ceramide in-
duced production of reactive oxygen species in a
concentration-dependent manner. It is known that DNA dam-
age caused by oxidative stress may activate PARP-1, a key
nuclear enzyme involved in DNA repair. Our results showed
PARP-1 activation and PAR polymer formation after C2-
ceramide treatment. Upon activation, PARP-1 transforms nic-
otinamide adenine dinucleotide (NAD+) into long PAR poly-
mers and transfers them to a variety of nuclear proteins, e.g.
histones, DNA polymerases and PARP-1 itself [21, 56–59].
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activation of PARP-1 leads to a 10- to 500-fold increase in
PAR polymer formation. The PAR polymer participates di-
rectly in cell death signalling. PAR is responsible for mito-
chondrial AIF release and caspase-independent apoptosis [21,
57, 58, 60]. The proper AIF level in mitochondria is very
important for the integration of proteins of electron transport
complexes. AIF is proposed to regulate the respiratory chain
indirectly, through assembly and/or stabilisation of complexes
C2-ceramide - - + + + +
S1P - + - + + +
W123 - - - - + -
VPC23019 - - - - - +
a b
c
Fig. 5 The effect of sphingosine-
1-phosphate (S1P {1 μM}) on
SH-SY5Y cell viability (a) and
ROS generation (b) after
incubation with C2-ceramide
(25 μM, 24 h). Data represent the
mean value±SEM for three
separate experiments with four to
six replications (a) and for three
separate experiments with three
replications (b). The effect of S1P
receptor antagonists (S1PR1-
W123 {20 μM} and S1PR3–
VPC23019 {1 μM}) on SH-
SY5Y cell viability after C2-
ceramide treatment (25 μM, 24 h)
(c). ***p<0.001 versus control
SH-SY5Y cells, ###p<0.001
versus C2-ceramide treated SH-
SY5Y cells, $$$p<0.001 versus
C2-ceramide and S1P treated SH-
SY5Y cells by using one-way
ANOVA followed by the
Newman-Keuls post hoc test
Fig. 6 Bcl-2 protein family
expression in SH-SY5Y cells
subjected to oxidative stress.
mRNA levels for Bcl-2 (a), Hrk
(b) and Bax (c) were evaluated
using real-time PCR after
incubation with C2-ceramide
(25 μM, 3 h). The value expresses
the fold of gene stimulation
normalised against Actb
(β-actin). Data represent themean
value±SEM for three separate
experiments with three
replications. **p<0.01, *p<0.05
versus control SH-SY5Y cells,
##p<0.01, #p<0.05 versus C2-
ceramide treated SH-SY5Y cells
by using one-way ANOVA
followed by the Newman-Keuls
post hoc test
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I and III [61–63]. The reduction in assembled complex I
associated with AIF deficiency is anticipated to have a pro-
found effect on mitochondrial function in neurons [64]. How-
ever, we ought to keep in mind that AIF after translocation to
nucleus exerted endonuclease activity and is responsible for
the DNA degradation into 50 kb fragments [65]. Our data
indicated that C2-ceramide caused the AIF release from mi-
tochondria, which was also observed in other experimental
conditions by [21–23, 37, 60, 65]. Our study showed that
PARP-1 inhibition significantly protected SH-SY5Y against
ceramide-induced cell death by reducing the level of ROS
production, thus preventing the AIF release from the mito-
chondria and increasing the mRNA level of anti-apoptotic
Bcl-2.Moreover, we observed enhancement of Bad phosphor-
ylation and down-regulation of Hrk gene expression. A pre-
vious study by Kauppinen et al. [66] showed that pharmaco-
logical inhibition of ERK1/2 prevented PARP-1 activation
and reduced PARP-1-mediated neuronal death. Our results
demonstrated that the inhibition of ERK1/2 kinases had a
small but statistically significant effect on cell viability. Be-
cause it is postulated that ceramide and S1P play a crucial role
in cell survival and death, the effect of exogenous S1P was
evaluated. It has been observed that S1P (1 μM) exerts its
inhibitory effect on apoptosis through members of the Bcl-2
protein family and the reduction of oxidative stress. The
present findings implicate a decrease in the mRNA level of
the pro-apoptotic (Hrk) proteins and an increase in the
mRNA/protein level of anti-apoptotic (Bcl-2) Bcl-2 proteins
as one of the mechanisms through which S1P protects SH-
SY5Y cells from apoptosis. These data are consistent with
studies on other cell types. It has been observed that exoge-
nous S1P regulates the expression of pro-apoptotic and anti-
apoptotic proteins; e.g. exogenous S1P increases the expres-
sion of the anti-apoptotic Bcl-2 [67] and Mcl-1 [68] while it
down-regulates the pro-apoptotic proteins Bad and Bax [69].















Fig. 7 The effect of PARP-1
inhibitor (PJ-34 {20 μM}) and
S1P (1 μM) on the Bcl-2 (a),
pBad (Ser136) and Bad (b)
protein level after incubation with
C2-ceramide (25 μM, 24 h). Data
represent the mean value±SEM
for three separate experiments
normalised against GAPDH.
Representative Western blots
from one typical experiment are
shown below the graphs. *p<0.05
versus control SH-SY5Y cells,
##p<0.01, #p<0.05 versus C2-
ceramide treated SH-SY5Y cells
by using one-way ANOVA
followed by the Newman-Keuls
post hoc test
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mitochondria [70]. Our study with specific S1P receptor an-
tagonists revealed that the pro-survival signal of S1P was
mainly dependent on S1PR1 and S1PR3 receptors. S1P sig-
nalling through these receptors may induce the activation of
the PI3K/Akt pathway [12, 13, 71]. It has been observed that
the activation of Akt can inhibit apoptosis by blocking the
release of AIF from the mitochondria [37]. Our data indicate
that such events as: activation of PARP-1, accumulation of
PAR and alteration of AIF level in mitochondria play a sig-
nificant role in the mechanism of apoptotic caspase-3 inde-
pendent cells death. As a conclusive remark, we suggest that
the modulators of sphingosine-1-phosphate receptor(s) and
PARP-1 inhibitor(s) should be considered in the therapy of
neurodegenerative disorders.
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